Top

Supportive Care in Cancer

Published in:

01-07-2007 | Original Article

The impact of an educational DVD on cancer patients considering participation in a phase I clinical trial

Authors: Elizabeth L. Strevel, Colin Newman, Gregory R. Pond, Martha MacLean, Lillian L. Siu

Published in: Supportive Care in Cancer | Issue 7/2007

Abstract

Goals of work

The quality of informed consent in phase I trials is controversial, partially due to gaps in patient understanding. We assessed an educational DVD’s impact on knowledge and satisfaction in cancer patients newly referred to a phase I clinic.

Materials and methods

Forty-nine patients were randomly assigned to view an educational DVD (n = 22) which explained phase I trials or a placebo DVD (n = 27). Patients completed a questionnaire assessing knowledge of phase I studies and satisfaction with the DVD. The blinded interviewing physician (n = 8) rated the patient’s understanding of phase I trials.

Main results

The mean patient age was 56; 61% were male. Patients who viewed the educational DVD were less likely to believe that phase I trials determine drug efficacy (p = 0.019), more likely to know that phase I drugs have not been thoroughly studied in humans (p = 0.003), and less likely to believe that these agents have proven activity against human cancers (p = 0.008). More patients who viewed the educational DVD agreed/strongly agreed that the DVD provided useful information (p < 0.001), were confident in their knowledge of phase I trials (p = 0.031), felt aided in their decision to enter a phase I study (p = 0.011), and would have more questions for their physicians because of the DVD (p = 0.017). No statistically significant difference in physician perception of patient understanding or phase I trial accrual was observed between the educational and placebo DVD groups.

Conclusions

An educational DVD increased patient knowledge and satisfaction regarding participation in phase I clinical trials.

Available only for authorised users

Agrawal M, Emanuel EJ (2003) Ethics of phase I oncology studies: Reexamining the arguments and data. JAMA 290:1075–1082PubMedCrossRef

Bain NS, Campbell NC, Ritchie LD et al (2002) Striking the right balance in colorectal cancer care—a qualitative study of rural and urban patients. Fam Pract 19:369–374PubMedCrossRef

Cheng JD, Hitt J, Koczwara B et al (2000) Impact of quality of life on patient expectations regarding phase I clinical trials. J Clin Oncol 18:421–428PubMed

Daugherty CK, Banik DM, Janish L et al (2000) Quantitative analysis of ethical issues in phase I trials: a survey interview study of 144 advanced cancer patients. IRB 22:6–14PubMedCrossRef

Daugherty C, Ratain MJ, Grochowski E et al (1995) Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol 13:1062–1072PubMed

Decoster G, Stein G, Holdener EE (1990) Responses and toxic deaths in phase I clinical trials. Ann Oncol 1:145–181

Eisenhauer EA, O’Dwyer PJ, Christian M et al (2000) Phase I clinical trial design in cancer drug development. J Clin Oncol 18:684–692PubMed

Emanuel EJ (1995) A phase I trial on the ethics of phase I trials. J Clin Oncol 13:1049–1051PubMed

Faden RR, Beauchamp TL, King NMP (1986) A history and theory of informed consent. Oxford University Press, New York, NY

10.

Flory J, Emanuel E (2004) Interventions to improve research participants’ understanding in informed consent for research: a systematic review. JAMA 292:1593–1601PubMedCrossRef

11.

Fureman I, Meyers K, McLellan AT et al (1997) Evaluation of a video-supplement to informed consent: injection drug users and preventive HIV efficacy trials. AIDS Educ Prev 9:330–341PubMed

12.

Hlubocky FJ, Kass NE, Fogarty LA et al (2004) Effects of a CD-ROM educational intervention (CD) on prognosis understanding among advanced cancer patients (acp) enrolling in early phase clinical trials. Proc Am Soc Clin Oncol 22:532s (Abstract 6054)

13.

Horstmann E, McCabe MS, Grochow L et al (2005) Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352:895–904PubMedCrossRef

14.

Hutchison C (1998) Phase I trials in cancer patients: participants’ perceptions. Eur J Cancer Care 7:15–22CrossRef

15.

Hutchison C, Campbell S (2002) Evaluation of an information booklet for patients considering participation in phase I clinical trials in cancer. Eur J Cancer Care 11:131–138CrossRef

16.

Itoh K, Sasaki Y, Fujii H et al (1997) Patients in phase I trials of anti-cancer agents in Japan: motivation, comprehension and expectations. Br J Cancer 76:107–113PubMed

17.

Itoh K, Sasaki Y, Miyata Y et al (1994) Therapeutic response and potential pitfalls in phase I clinical trials of anticancer agents conducted in Japan. Cancer Chemother Pharmacol 4:451–454

18.

Joffe S, Miller FG (2006) Rethinking risk-benefit assessment for phase I cancer trials. J Clin Oncol 24:2987–2990PubMedCrossRef

19.

Meade CD (1999) Improving understanding of the informed consent process and document. Sem Oncol Nurs 15:124–137CrossRef

20.

Meropol NJ, Weinfurt KP, Burnett CB et al (2003) Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician–patient communication. J Clin Oncol 21:2589–2596PubMedCrossRef

21.

Nitschke R (2004) Physician–patient communication in phase I cancer trials. J Clin Oncol 22:571–572PubMedCrossRef

22.

Nurgat ZA, Craig W, Campbell NC et al (2005) Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy. Br J Cancer 92:1001–1005PubMedCrossRef

23.

Penman DT, Holland JC, Bahna GF et al (1984) Informed consent for investigational chemotherapy: patients’ and physicians’ perceptions. J Clin Oncol 2:849–855PubMed

24.

Rajagopal S, Goodman PJ, Tannock IF (1994) Adjuvant chemotherapy for breast cancer: discordance between physicians’ perception of benefit and the results of clinical trials. J Clin Oncol 12:1296–1304PubMed

25.

Roberts Jr TG, Goulart BH, Squitieri L et al (2004) Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 292:2130–2140PubMedCrossRef

26.

Rodenhuis S, van den Heuvel WJA, Annyas AA et al (1984) Patient motivation and informed consent in a phase I study of an anticancer agent. Eur J Cancer Clin Oncol 20:457–462PubMedCrossRef

27.

Rossi M, McClellan R, Chou L et al (2004) Informed consent for ankle fracture surgery: patient comprehension of verbal and videotaped information. Foot Ankle Int 25:756–762PubMed

28.

Von Hoff DD, Turner J (1991) Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs 9:115–122

29.

Weeks JC, Cook EF, O’Day SJ et al (1998) Relationship between cancer patients’ predictions of prognosis and their treatment preferences. JAMA 279:1709–1714PubMedCrossRef

30.

Weinfurt KP, Castel LD, Li Y et al (2003) The correlation between patient characteristics and expectations of benefit from phase I clinical trials. Cancer 98:166–175PubMedCrossRef

31.

Weston J, Hannah M, Downes J (1997) Evaluating the benefits of a patient information video during the informed consent process. Patient Educ Couns 30:239–245PubMedCrossRef

32.

Wirshing DA, Sergi MJ, Mintz J (2005) A videotape intervention to enhance the informed consent process for medical and psychiatric treatment research. Am J Psychiatr 162:186–188PubMedCrossRef

33.

Yoder LH, O’Rourke TJ, Etnyre A et al (1997) Expectations and experiences of patients with cancer participating in phase I clinical trials. Oncol Nurs Forum 24:891–896PubMed

Title: The impact of an educational DVD on cancer patients considering participation in a phase I clinical trial
Authors: Elizabeth L. Strevel
Colin Newman
Gregory R. Pond
Martha MacLean
Lillian L. Siu
Publication date: 01-07-2007
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 7/2007
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-006-0199-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Goals of work

Materials and methods

Main results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2007

Phase I participants’ views of quality of life and trial participation burdens

The current status of palliative care teams in Japanese University Hospitals: a nationwide questionnaire survey

Ways to obtain a breast cancer diagnosis, consistency of information, patient satisfaction, and the presence of relatives

Factors related to anxiety and depression in women with breast cancer and their husbands: role of alexithymia and family functioning

Reluctance to disclose difficult diagnoses: a narrative review comparing communication by psychiatrists and oncologists

Childhood cancer—are there predictors of parental well-being?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer